An enhanced contrast in magnetic resonance imaging (MRI) with high specificity and low toxicity is of great importance in the accurate diagnosis and delineation of gliomas for improved outcomes. In this study, a glioma-targeted contrast agent was designed and prepared by conjugating chlorotoxin (CTX) to poly(ethylene glycol) (PEG) coated Gd2O3 nanoparticles (CTX-PEG-Gd2O3 NPs). The r1 value of CTX-PEG-Gd2O3 NPs was measured to be 8.41 mM−1 s−1, which is higher than that of commercially available Gd-DTPA (4.57 mM−1 s−1). The T1 contrast enhancement with a prolonged retention period up to 24 h within the brain glioma due to CTX conjugation was demonstrated. Moreover, cell viability and histological analysis verified the low cytotoxicity and the good biocompatibility of CTX-PEG-Gd2O3 NPs. Therefore, our study nominates CTX-PEG-Gd2O3 NPs as a promising glioma-targeted T1 contrast agent that allows more accurate diagnosis and delineation of brain gliomas.
2 January 2021 in Journal of Cancer Research and Clinical Oncology
Purpose: Supratentorial extraventricular ependymoma (SEE) is a rare subset of ependymomas located in the supratentorial parenchyma, and little is known regarding its management and prognosis. Our study aimed to reveal the prognostic factors in patients with SEE and the roles of programmed death ligand-1 (PD-L1), programmed cell death protein 1 (PD-1), Ki-67, and neural cell adhesion molecule L1 (L1CAM) in predicting these patients’ outcomes. Methods: We retrospectively studied the clinical features and prognostic factors in 48 patients with SEE admitted to our center from April 2008 to October 2018. Tissue slides were constructed from patient samples, and PD-L1, PD-1, Ki-67, and L1CAM expression levels were evaluated by immunohistochemistry. Results: Patients with gross total resection (GTR) had better progression-free survival than patients with subtotal resection (STR). Moreover, the recurrence hazard ratios in patients with STR at 3, 5, and 10 years were 8.746, 6.866 and 3.962 times those of patients with GTR, respectively. PD-L1 positivity predicted worse progression-free survival, while the recurrence hazard ratios for patients with PD-L1 positivity at 3, 5, and 10 years were 10.445, 5.539, and 3.949 times those of patients with PD-L1 negativity, respectively. Multivariate analysis revealed that PD-L1 expression and GTR could independently predict outcomes in patients with SEE. Conclusion: PD-L1 expression was an independent and more readily obtained predictor of outcomes, representing a simple and reliable biological prognostic factor for patients with SEE. Further studies are needed to explore PD-L1 inhibitor treatment for patients with ependymoma. Clinical trial registration: No clinical trials were performed in the study.
Solitary fibrous tumors (SFTs) of the central nervous system (CNS) are rare, aggressive mesenchymal neoplasms with high recurrence and metastasis rates. Here, we perform a comprehensive multi-omics analysis of 189 cases of CNS SFTs integrating 94 whole genome sequencing, 88 transcriptomics, 7 single-nucleus RNA sequencing and 3 spatial transcriptome sequencing. We find that receptor tyrosine kinase mutations are significantly more prevalent besides the widespread NAB2-STAT6 fusion and correlate with tumor grade. Transcriptomic analysis reveals four molecular subtypes—classical, neural-like, inflamed and migratory—each associated with distinct clinical and biological characteristics. Single-nucleus RNA sequencing identifies five tumor cell states, with the SFT_classical state serving as a precursor to other states influenced by hypoxia and inflammation. Notably, we identify FER kinase as a key therapeutic target, with FER inhibition significantly reducing tumor cell proliferation, migration and invasion. These findings provide important insights into CNS SFT biology and suggest potential therapeutic strategies for this challenging tumor type.